You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

YONSA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Yonsa, and what generic alternatives are available?

Yonsa is a drug marketed by Sun Pharm and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-eight patent family members in twenty-six countries.

The generic ingredient in YONSA is abiraterone acetate. There are twenty-five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the abiraterone acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Yonsa

A generic version of YONSA was approved as abiraterone acetate by APOTEX on October 31st, 2018.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for YONSA?
  • What are the global sales for YONSA?
  • What is Average Wholesale Price for YONSA?
Drug patent expirations by year for YONSA
Drug Prices for YONSA

See drug prices for YONSA

Paragraph IV (Patent) Challenges for YONSA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
YONSA Tablets abiraterone acetate 125 mg 210308 1 2018-07-23

US Patents and Regulatory Information for YONSA

YONSA is protected by two US patents.

Patents protecting YONSA

Abiraterone steroid formulation
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN COMBINATION WITH METHYLPREDNISOLONE FOR THE TREATMENT OF PATIENTS WITH PROSTATE CANCER

Abiraterone acetate formulation and methods of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm YONSA abiraterone acetate TABLET;ORAL 210308-001 May 22, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sun Pharm YONSA abiraterone acetate TABLET;ORAL 210308-001 May 22, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for YONSA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Mylan Ireland Limited Abiraterone Mylan abiraterone acetate EMEA/H/C/005368
Abiraterone Mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
Authorised yes no no 2021-08-20
Krka, d.d., Novo mesto Abiraterone Krka abiraterone acetate EMEA/H/C/005649
Abiraterone Krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1)the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1)the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
Authorised yes no no 2021-06-24
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for YONSA

When does loss-of-exclusivity occur for YONSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 5480
Patent: FORMULACIÓN DE ACETATO DE ABIRATERONA
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 14232508
Patent: Abiraterone acetate formulation
Estimated Expiration: ⤷  Sign Up

Patent: 15317466
Patent: Abiraterone acetate formulation and methods of use
Estimated Expiration: ⤷  Sign Up

Patent: 18241103
Patent: Abiraterone Acetate Formulation
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2015023629
Patent: formulação de acetato de abiraterona
Estimated Expiration: ⤷  Sign Up

Patent: 2017003219
Patent: formulação de acetato de abiraterona e métodos de uso
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 07415
Patent: FORMULATION D'ACETATE D'ABIRATERONE (ABIRATERONE ACETATE FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 58316
Patent: FORMULATION D'ACETATE D'ABIRATERONE ET SES PROCEDES D'UTILISATION (ABIRATERONE ACETATE FORMULATION AND METHODS OF USE)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 15002787
Patent: Formulación de acetato de abiraterona.
Estimated Expiration: ⤷  Sign Up

China

Patent: 5246598
Patent: Abiraterone acetate formulation
Estimated Expiration: ⤷  Sign Up

Patent: 6687112
Patent: 醋酸阿比特龙制剂和使用方法 (Abiraterone acetate formulation and methods of use)
Estimated Expiration: ⤷  Sign Up

Patent: 0604721
Patent: 乙酸阿比特龙酯制剂 (Abiraterone acetate preparation)
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 17002472
Patent: Formulación de acetato de abiraterona
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 1790650
Patent: ЛЕКАРСТВЕННАЯ ФОРМА И СПОСОБЫ ПРИМЕНЕНИЯ АБИРАТЕРОНА АЦЕТАТА
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 69227
Patent: FORMULATION D'ACÉTATE D'ABIRATÉRONE (ABIRATERONE ACETATE FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 93857
Patent: FORMULATION D'ACÉTATE D'ABIRATÉRONE ET SES PROCÉDÉS D'UTILISATION (ABIRATERONE ACETATE FORMULATION AND METHODS OF USE)
Estimated Expiration: ⤷  Sign Up

Patent: 78266
Patent: FORMULATION D'ACÉTATE D'ABIRATÉRONE (ABIRATERONE ACETATE FORMULATION)
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 19457
Patent: 乙酸阿比特龍酯製劑 (ABIRATERONE ACETATE FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 20162
Patent: 乙酸阿比特龍酯製劑 (ABIRATERONE ACETATE FORMULATION)
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 1612
Patent: פורמולציה של אבירטרון אצטאט (Abiraterone acetate formulation)
Estimated Expiration: ⤷  Sign Up

Patent: 0270
Patent: פורמולציות אבירטרון אצטט ושיטות שימוש (Abiraterone acetate formulation and methods of use)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 20485
Estimated Expiration: ⤷  Sign Up

Patent: 16514707
Patent: アビラテロン酢酸エステル製剤
Estimated Expiration: ⤷  Sign Up

Patent: 17528457
Patent: 酢酸アビラテロン製剤及び使用方法
Estimated Expiration: ⤷  Sign Up

Patent: 18135351
Patent: アビラテロン酢酸エステル製剤 (ABIRATERONE ACETATE FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 21008521
Patent: アビラテロン酢酸エステル製剤 (ABIRATERONE ACETATE FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 23103410
Patent: アビラテロン酢酸エステル製剤 (ABIRATERONE ACETATE FORMULATION)
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 15013247
Patent: FORMULACION DE ACETATO DE ABIRATERONA. (ABIRATERONE ACETATE FORMULATION.)
Estimated Expiration: ⤷  Sign Up

Patent: 17003525
Patent: FORMULACION DE ACETATO DE ABIRATERONA Y METODOS DE USO. (ABIRATERONE ACETATE FORMULATION AND METHODS OF USE.)
Estimated Expiration: ⤷  Sign Up

Moldova, Republic of

Patent: 170048
Patent: Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia (Abiraterone acetate formulation and methods of use)
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 521
Patent: Formulation d'acétate d'abiratérone utilisé dans le traitement du cancer de la prostate resistant a la castration
Estimated Expiration: ⤷  Sign Up

Patent: 116
Patent: Formulation d'acétate d'abiratérone et ses procédés d'utilisation
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 2350
Patent: Abiraterone acetate formulation
Estimated Expiration: ⤷  Sign Up

Philippines

Patent: 017500239
Patent: ABIRATERONE ACETATE FORMULATION AND METHODS OF USE
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 69227
Estimated Expiration: ⤷  Sign Up

Russian Federation

Patent: 32136
Patent: СОСТАВ НА ОСНОВЕ АБИРАТЕРОНА АЦЕТАТА (ABIRATERONE ACETATE FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 15144285
Patent: СОСТАВ НА ОСНОВЕ АБИРАТЕРОНА АЦЕТАТА
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201709400V
Patent: ABIRATERONE ACETATE FORMULATION
Estimated Expiration: ⤷  Sign Up

Patent: 201507681P
Patent: ABIRATERONE ACETATE FORMULATION
Estimated Expiration: ⤷  Sign Up

Patent: 201701139Y
Patent: ABIRATERONE ACETATE FORMULATION AND METHODS OF USE
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1507209
Patent: ABIRATERONE ACETATE FORMULATION
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2121404
Estimated Expiration: ⤷  Sign Up

Patent: 2491439
Estimated Expiration: ⤷  Sign Up

Patent: 2617537
Estimated Expiration: ⤷  Sign Up

Patent: 160023641
Patent: 아비라테론 아세테이트 제제 (ABIRATERONE ACETATE FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 170070025
Patent: 아비라테론 아세테이트 제제 및 사용 방법 (ABIRATERONE ACETATE FORMULATION AND METHODS OF USE)
Estimated Expiration: ⤷  Sign Up

Patent: 180021932
Patent: 아비라테론 아세테이트 제제 (ABIRATERONE ACETATE FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 190141270
Patent: 아비라테론 아세테이트 제제 (ABIRATERONE ACETATE FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 230014878
Patent: 아비라테론 아세테이트 제제 및 사용 방법 (ABIRATERONE ACETATE FORMULATION AND METHODS OF USE)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 41800
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 86212
Estimated Expiration: ⤷  Sign Up

Patent: 31321
Estimated Expiration: ⤷  Sign Up

Patent: 1513896
Patent: Abiraterone acetate formulation
Estimated Expiration: ⤷  Sign Up

Patent: 1943408
Patent: Abiraterone acetate formulation
Estimated Expiration: ⤷  Sign Up

Tunisia

Patent: 17000098
Patent: ABIRATERONE ACETATE FORMULATION AND METHODS OF USE.
Estimated Expiration: ⤷  Sign Up

Patent: 18000318
Patent: ABIRATERONE ACETATE FORMULATION AND METHODS OF USE.
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering YONSA around the world.

Country Patent Number Title Estimated Expiration
Chile 2015002787 Formulación de acetato de abiraterona. ⤷  Sign Up
Israel 250270 פורמולציות אבירטרון אצטט ושיטות שימוש (Abiraterone acetate formulation and methods of use) ⤷  Sign Up
Japan 2021008521 アビラテロン酢酸エステル製剤 (ABIRATERONE ACETATE FORMULATION) ⤷  Sign Up
South Korea 102121404 ⤷  Sign Up
Tunisia 2018000318 ABIRATERONE ACETATE FORMULATION AND METHODS OF USE. ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2014145813 ⤷  Sign Up
Spain 2741800 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for YONSA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0633893 SPC/GB11/063 United Kingdom ⤷  Sign Up PRODUCT NAME: ABIRATERONE AND ACID ADDITION SALTS AND 3-ESTERS THEREOF ESPECIALLY ABIRATERONE ACETATE; REGISTERED: UK EU/1/11/714/001 20110905
0633893 2012/003 Ireland ⤷  Sign Up PRODUCT NAME: ZYTIGA (ABIRATERONE) "ABIRATERONE AND ACID ADDITION SALTS AND 3-ESTERS THEREOF, ESPECIALLY ABIRATERONE ACETATE"; REGISTRATION NO/DATE: EU/1/11/714/001 20110905
0633893 11C0055 France ⤷  Sign Up PRODUCT NAME: ABIRATERONE, SES SELS D'ADDITION D'ACIDE ET 3-ESTERS, EN PARTICULIER ACETATE D'ABIRATERONE; REGISTRATION NO/DATE: EU/1/11/714/001 20110905
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.